Hot
melt extrusion (HME) has become an essential technology to
cope with an increasing number of poorly soluble drug candidates.
However, there is only a limited choice of pharmaceutical polymers
for obtaining suitable amorphous solid dispersions (ASD). Considerations
of miscibility, stability, and biopharmaceutical performance narrow
the selection of excipients, and further technical constraints arise
from needed pharmaceutical processing. The present work introduces
the concept of molecularly targeted interactions of a coformer with
a polymer to design a new matrix for HME. Model systems of dimethylaminoethyl
methacrylate copolymer, Eudragit E (EE), and bicarboxylic acids were
studied, and pronounced molecular interactions were demonstrated by 1H, 13C NMR, FTIR spectroscopy, as well as by different
techniques of microscopic imaging. A difference was shown between
new formulations exploiting specifically the targeted molecular interactions
and a common drug–polymer formulation. More specifically, a
modified matrix with malic acid exhibited a technical extrusion advantage
over polymer alone, and there was a benefit of improved physical stability
revealed for the drug fenofibrate. This model compound displayed greatly
enhanced dissolution kinetics from the ASD formulations. It can be
concluded that harnessing molecularly designed polymer modifications
by coformers has much potential in solid dispersion technology and
in particular regarding HME processing.